Skip to main content
Have a personal or library account? Click to login
Mannan-coated gelatin nanoparticles for sustained and targeted delivery of didanosine: In vitro and in vivo evaluation Cover

Mannan-coated gelatin nanoparticles for sustained and targeted delivery of didanosine: In vitro and in vivo evaluation

Open Access
|Mar 2008

References

  1. M. S. Meltzer, D. R. Skillman, P. J. Gomatos, D. C. Kalter and H. C. Gendelman, Role of mononuclear phagocytosis in the pathogenesis of human immunodeficiency virus infection,(1990)169-194; DOI: 10.1146/annurev.iy.08.040190.001125.
  2. S. Aquaro, R. Calio, J. Balzarini, M. C. Bellocchi, E. Garaci and C. F. Perno, Macrophages and HIV infection: therapeutical approaches toward this strategic virus reservoir,(2002) 209-225; DOI: 10.1016/S0166-3542(02)00052-9.
  3. C. Oussoren, M. Magnani, A. Fraternale, A. Casabianca, L. Chiarantini, R. Ingebrigsten, W. J. M. Underberg and G. Strome, Liposomes as carrier of the antiretroviral agent dideoxycytidine-5'-triphosphate,(1999) 261-270; DOI: 10.1016/S0378-5173(99)00016-2.
  4. V. Schafer, H. V. Briesen, H. Rubsamen-Waigmann, A. M. Steffan, C. Royer and J. Kreuter, Phagocytosis and degradation of human serum albumin microspheres and nanoparticles in human macrophages,(1994) 261-269; DOI: 10.3109/02652049409040455.
  5. Z. Cui, C. H. Hsu and R. J. Mumper, Physical characterization and macrophage cell uptake of mannan-coated nanoparticles,(2003) 689-700; DOI: 10.1081/DDC-120021318.
  6. F. Ahsan, I. P. Rivas, M. A. Khan and A. I. T. Suarez, Targeting of macrophage: role of physicochemical properties of particulate carriers-liposomes and microsphere on the phagocytosis by macrophages,(2002) 29-40; DOI: 10.1016/S0168-3659(01)00549-1.
  7. J. Kreuter, Nanoparticulate system for brain delivery of drugs,(2001) 65-81; DOI: 10.1016/S0169-409X(00)00122-8.
  8. M. S. Wadhwa and K. G. Rice, Receptor mediated glycotargeting,(2003) 255-268; DOI: 10.1080/10611860310001636557.
  9. J. Shao and J. K. H. Ma, Characterization of mannosylphospholipid liposome system for drug targeting to alveolar macrophages,(1997) 43-48.
  10. Y. Gabr, N. Assem, A. Micheal and L. Fahmy, Evaluation studies on oxypolygelatin and degraded gelatin as plasma volume expanders,(1996) 763-766.
  11. R. Yarchoan, H. Mitsuya, R. V. Thomas, J. M. Pluda, N. R. Hartman and C. F. Perno, In vivo activity against HIV and favorable toxicity profile of 2'3'-dideoxyinosine,(1989) 412-417.
  12. T. P. Cooley, M. L. Kunches, C. A. Saunders, C. J. Perkins, S. L. Kelley, C. McLaren, R. P. McCaffrey and H. A Liebman, Treatment of AIDS and AIDS related complex with 2'3'-dideoxyinosine given once daily,(1990) S552-S560.
  13. C. J. Coester, K. Langer, H. Von Briesen and J. Kreuter, Gelatin nanoparticles by two step desolvation - A new preparation method, surface modification and cell uptake,(2000) 187-193; DOI: 10.1080/026520400288427.
  14. J. Vandervoort and A. Ludwig, Preparation and evaluation of drug-loaded gelatin nanoparticles for topical ophthalmic use,(2004) 251-261; DOI: 10.1016/S0939-6411(03)00187-5.
  15. E. Rebasamen, W. Goldinger, W. Scheirer, O. W. Merten and G. E. Palfe,(Eds. R. Spier and W. Hennessen), Vol., ESACT, Basel 1987, pp. 557-583.
  16. V. F. Courtney, R. C. Brundage, R. P. Remmel, L. M. Page, D. Weller, N. R. Calles, C. Simon and M. W. Kline, Pharmacologic characteristic of indinavir, didanosine and stavudine in human immunodeficiency virus-infected children receiving combination therapy,(2000) 1029-1034.
  17. S. Jain, R. Sapre, A. K. Tiwary and N. K. Jain, Proultraflexible lipid vesicles for effective transdermal delivery of levonorgestrel: Development, characterization and performance evaluation, AAPS(2005) E513-E522; DOI: 10.1208/pt060364.
  18. S. Kaul, W. C. Shyu, U. A. Shukla, K. A. Dandekar and R. H. Barbhaiya, Pharmacologic characteristic of indinavir, didanosine and stavudine in human immunodeficiency Virus-Infected children receiving combination therapy,(1993) 447-453.
  19. E. Mukherji, N. J. Millenbaugh and J. L. S. Au, Percutaneous absorption of 2',3'-dideoxyinosine in rats,(1994) 809-815.
  20. O. Bekers, J. H. Beijnen, M. J. T. Klein Tank, D. M. Burger, P. I. Meenhorst, A. J. P. F. Lombarts and W. J. M. Underberg, 2',3'-dideoxyinosine (ddI): Its chemical stability and cyclodextrin complexation in aqueous media,(1993) 489-493; DOI: 10.1016/0731-7085(93)80162-T.
  21. P. T. Tayade and R. D. Kale, Encapsulation of water-insoluble drug by a cross-linking technique: Effect of process and formulation variables on encapsulation efficiency, particle size, anddissolution rate, AAPS(2004); DOI: 10.1208/ps060112.
  22. C. Sanchez-Lafuente, A. M. Rabasco, J. Alvarez-Fuentes and M. Fernandez-Arevalo, Eudragit® RS-PM and Ethocel® 100 premium: influence over the behavior of didanosine inert matrix system,(2002) 649-656; DOI: 10.1016/S0014-827X(02)01240-5.
  23. V. Apostolopoulos and I. F. McKenzie, Role of the mannose receptor in the immune response,(2001) 469-474; DOI:10.2174/1566524013363645.
  24. C. A. Hoppe and Y. C. Lee, The binding and processing of mannose-bovine serum albumin derivatives by rabbit alveolar macrophages. Effect of the sugar density,(1983) 14193-14199.
  25. M. Velinova, N. Read, C. Kirby and G. Gregoriadis, Morphological observation on the fate of liposomes in the regional lymph nodes after footpad injection into rats,(1996) 207-215; DOI: 10.1016/0005-2760(95)00208-1.
DOI: https://doi.org/10.2478/v10007-007-0045-1 | Journal eISSN: 1846-9558 | Journal ISSN: 1330-0075
Language: English, Croatian
Page range: 61 - 74
Published on: Mar 12, 2008
Published by: Croatian Pharmaceutical Society
In partnership with: Paradigm Publishing Services
Related subjects:

© 2008 Amandeep Kaur, Subheet Jain, Ashok Tiwary, published by Croatian Pharmaceutical Society
This work is licensed under the Creative Commons License.